MacroGenics Inc. reported its financial results for the quarter ended March 31, 2025. The company achieved total revenues of $13.192 million, showing an increase from $9.104 million in the same quarter of the previous year. This rise in revenues was primarily driven by collaborative and other agreements, which contributed $7.042 million, up from $1.609 million in the previous year's corresponding period. Contract manufacturing also increased to $6.150 million from $2.276 million. The net loss for the quarter was $41.036 million, a reduction from the $52.190 million net loss posted in the same quarter of 2024. This decrease in net loss can be attributed to lower costs and expenses, including a reduction in research and development expenses from $46.029 million to $39.698 million, and a decrease in selling, general, and administrative expenses from $14.709 million to $10.718 million. MacroGenics also reported that its cash, cash equivalents, and marketable securities stood at $154.1 million as of March 31, 2025. The company provided cash runway guidance indicating that this balance, along with anticipated future payments from partners, will support its operations into the second half of 2026. The company is continuing to focus on planned investments in ongoing clinical and preclinical programs and has implemented cost-saving measures to extend its financial runway. The company did not host a conference call to discuss these results but may resume such calls in the future.